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Head and neck cancer
Microvascular reconstruction
Complicationsa b s t r a c t
Objectives: Glucocorticoids are widely used in association with major surgery of the head and neck to
improve postoperative rehabilitation, shorten intensive care unit and hospital stay, and reduce neck
swelling. This study aimed to clarify whether peri- and postoperative use of dexamethasone in recon-
structive head and neck cancer surgery is associated with any advantages or disadvantages.
Materials and methods: This prospective double-blind randomized controlled trial comprised 93 patients.
A total dose of 60 mg of dexamethasone was administered to 51 patients over three days peri- and post-
operatively. The remaining 42 patients served as controls. The main primary outcome variables were
neck swelling, length of intensive care unit and hospital stay, duration of intubation or tracheostomy,
and delay to start of possible radiotherapy. Complications were also recorded.
Results: No statistical differences emerged between the two groups in any of the main primary outcome
variables. However, there were more major complications, especially infections, needing secondary sur-
gery within three weeks of the operation in patients receiving dexamethasone than in control patients
(27% vs. 7%, p = 0.012).
Conclusions: The use of dexamethasone in oral cancer patients with microvascular reconstruction did not
provide a benefit. More major complications, especially infections, occurred in patients receiving dexam-
ethasone. Our data thus do not support the use of peri- and postoperative dexamethasone in oropharyn-
geal cancer patients undergoing microvascular reconstruction.
 2016 Elsevier Ltd. All rights reserved.Introduction
Treatment of oropharyngeal carcinoma causes major morbidity.
Treatment modalities include surgery, radiation, and chemother-
apy. In surgery, microvascular tissue reconstruction has become
the definitive method to cover large defects after tumor resection.
Reconstruction improves the healing and is essential to restore oral
function and esthetics, thereby improving the quality of life after
an extensive surgical procedure [1–8]. Oropharyngeal tumor sur-
gery is associated with many postoperative problems like respira-
tory problems, major swelling, prolonged length of tracheostomy,
and lengthened intensive care unit and hospital stay. A major goal
in treatment is to achieve primary healing without delaying possi-
ble adjuvant radiotherapy.Glucocorticoids (GCs) are widely used in association with head
and neck surgery to reduce these undesirable problems due their
anti-inflammatory effects [9–11]. GCs improve postoperative reha-
bilitation, shorten intensive care unit and hospital stay, and reduce
neck swelling. However, adverse effects may follow GC use, partic-
ularly when high doses are used. Short-term GC use has been
reported to increase the risk for avascular necrosis of the femoral
head, steroid-induced psychosis, peptic ulcers, and gastrointestinal
bleeding [12–21]. Another considerable disadvantage of steroids is
impaired wound healing, which may increase postoperative infec-
tions and complications [22–24]. Despite the well-documented
efficacy of systemic dexamethasone usage in surgery, no data exist
regarding effects and safety of dexamethasone in oropharyngeal
cancer reconstructive surgery.
We performed a prospective randomized double-blind control
study to examine whether the peri- and postoperative use of dex-
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associated with advantages or disadvantages.Materials and methods
A prospective double-blind randomized controlled trial was
conducted between December 2008 and February 2013 at the
Department of Oral and Maxillofacial Surgery and the Department
of Plastic Surgery, Helsinki University Hospital, Finland. The study
protocol was approved by the Research Ethics Committee of Hel-
sinki University Hospital. Written informed consent was obtained
from all patients before surgery.
Consecutive patients with oropharyngeal cancer who had a
microvascular reconstruction were included in the study. Exclu-
sion criteria were history of liver or kidney dysfunction, glaucoma,
peptic ulcer, psychosis from use of steroids, allergy to any con-
stituent of the dexamethasone preparation used, and absence of
written informed consent. We collected consecutive 110 patients,
55 to each group. Ninety-seven patients met the inclusion criteria.
Four of these patients were subsequently excluded, three because
of intraoperative cancellation of free flap reconstruction and one
because he was administered additional dexamethasone. There-
fore, 93 patients were included in the study, 73 from the Depart-
ment of Maxillofacial Surgery and 20 from the Department of
Plastic Surgery. Of the 93 patients, 51 had received dexamethasone
(DEX-group) and 42 had not received dexamethasone and were the
control group (NON-DEX). The discrepancy in the size of two
groups is explained by the effect of luck since patients were chosen
to either group by random selection.
Patients were randomly allocated into two groups. The patients
in the study group received dexamethasone (Oradexon) 10 mg
intravenously (i.v.) every 8 h on the first day, every 12 h on the sec-
ond day, and one dose on the third day, receiving a total dose of
60 mg (DEX). The patients in the control group received no dexam-
ethasone (NON-DEX). The randomization was done by a nurse not
participating in the study. The information about whether a patient
would receive dexamethasone was given in a sealed envelope to
the anesthesiologist in charge of the anesthesia of the surgery.
The same anesthesiologist administered all doses to the patient if
allocated during the operation and in the ICU postoperatively. Sur-
geons were unaware of the group to which patients were assigned.
Preoperative and predictive data in DEX and NON-DEX groups
are given in Table 1. The majority (92%) of tumors were squamous
cell carcinomas. The oral tongue and mandible were the most com-
mon sites of malignancy, each affected in 29% of cases. These were
followed by the maxilla (16%), floor of the mouth (12%), buccal
mucosa (10%), tonsilla (3%), palate (1%), and larynx – hypopharynx
(1%). There were 83 fasciocutaneous and 10 osseofasciocutaneous
reconstructions. The radial forearm (RFF) was the most frequently
performed flap (31 in DEX, 20 in NON-DEX), followed by the
anterolateral thigh (ALT) perforator flap (15 in DEX, 18 in NON-
DEX). The other flap types included the deep circumflex iliac artery
(DCIA) bone flap, fibula free flap, latissimus dorsi (LD) muscle flap,
and scapula or parascapular flaps. The surgical data are given in
Table 2 and TNM classifications in Table 5. We classified surgical
complications according to Dindo et al. so that all major complica-
tions were included to complication group IIIb or worse and
received secondary surgery within three weeks [25,26].
All patients received standard, balanced anesthesia. Patients
received cefuroxime 1.5 g  3 i.v. and metronidazole 500 mg
1  3 i.v. over an average of 7 days, starting from induction of gen-
eral anesthesia. Patients with allergies were given clindamycin
300 mg  4 i.v. In the postoperative period, patients were given
paracetamol 1 g  3 i.v. No non-steroidal anti-inflammatory drugs
were used. Postoperatively, oxycodone 0.2–0.4 mg/10 kg i.v. wasadministered if the patient scored more than 4 on a Visual Analog
Scale (VAS) or when requested by the patient. Postoperative nau-
sea was treated with ondansetron as needed. One physician (SK)
collected and sorted the data from the follow-up forms and hospi-
tal database.Statistical analysis
Significance of associations between groups and categorical
variables was evaluated by Chi-square tests. Differences in mean
values between groups and continuous variables were evaluated
by Student’s t-tests for normally distributed variables and by Wil-
coxon two-sample test for variables with skewed distributions. To
indicate overall recovery from the surgery, a score was formed that
included the following 12 continuous variables: change in neck cir-
cumference, start of using Heat and Moisture Exchanger (HME),
time of decannulation of tracheostomy/extubation, neck drainage
removal time, start of communication, sitting, standing, walking,
drinking fluids, transferring to the hospital ward and home, and
change in patient’s weight during hospital stay. Each variable
was at first categorized according to median value (1 if 6median
and +1 if > median). A sum score of these was calculated and fur-
ther dichotomized according to median value (medianP 7; 1 indi-
cating shorter/better recovery, medianP 7; 0 indicating longer/
poorer recovery, median < 7) to serve as an outcome in logistic
regression analysis. Explanatory variables included group (NON-
DEX or DEX), age as continuous, sex, Body Mass Index (BMI), his-
tory of alcohol use (major, moderate, or none), length of surgery,
American Society of Anesthesiologists (ASA) score, and major com-
plications. We did a power analysis to evaluate the statistical reli-
ability of the present study.Results
No statistical differences existed between the DEX and NON-
DEX groups regarding preoperative demographic data or preoper-
ative treatments given to patients, except that there were more
heavy alcohol users in the NON-DEX group (DEX n = 8 (16%),
NON-DEX n = 13 (31%), p = 0.113). Localizations of the tumors,
TNM classifications, and surgical defects were similar between
the groups. The flap types used as well as the neck dissection types
and operation times were also similar between DEX and NON-DEX
groups. In the NON-DEX group, more patients were tra-
cheostomized at the beginning the operation than in the DEX
group (60% vs. 33%, p = 0.034). Postoperative adjuvant treatments
were similar in both groups. There were more diabetics in the
DEX group, however this difference was not statistically significant
(Tables 1 and 2).
The main primary outcome variables were neck swelling, length
of intensive care unit stay and hospital stay, duration of intubation
or tracheostomy, and delay to start of radiotherapy. No statistical
differences existed between the two groups in any of these vari-
ables. Patients’ neck swelling was measured daily from the highest
point of the neck for seven days postoperatively, and the highest
increase in neck circumference (cm) relative to the preoperative
circumference was used in analysis. Length of tracheostomy was
three days shorter (23%) in the DEX group, but the difference
was not significant. Four primarily intubated patients in the DEX
group and one patient in the NON-DEX group were tra-
cheostomized postoperatively due to prolonged need for mechan-
ically assisted ventilation. Therefore, the total number of
tracheostomies was 21/51 patients (41%) in the DEX group and
26/42 patients (62%) in the NON-DEX group (Table 3).
The DEX group had more major complications during the post-
operative period (27% in DEX vs. 7% in NON-DEX, p = 0.012). The
Table 1
Patient data.
All (n = 93) DEX (n = 51) NON-DEX (n = 42) P
Demographic characteristics and comorbidities
Age (years) 65 (34–93) 65 (39–93) 65 (34–88) 0.798
Male/Female 59/34 32/19 27/15 0.878
BMI 24.9 (15.8–42.7) 25.5 (15.8–42.70) 24.5 (17.0–32.6) 0.331
ASA (1/2/3/4) 6/23/48/13 3/10/27/11 3/13/21/4 0.339
History of alcohol use (major/moderate/no) 21/45/27 8/23/20 13/22/7 0.038
History of smoking (yes/no) 37/56 19/32 18/24 0.583
CCI (0–1/2–4/5–9) 49/29/15 24/19/8 25/10/7 0.363
Diabetes 15/93 (18%) 11/51 (22%) 4/42 (10%) 0.116
Preoperative characteristics
Previous radiotherapy 9/93 (10%) 5 (10%) 4 (10%) 0.939
Previous chemotherapy 3/93 (3%) 1/51 (2%) 2/42 (5%) 0.447
Previous operation in same area 14/91 (15%) 10/49 (20%) 4/42 (10%) 0.151
Perioperative data
Tracheostomy / intubation 47 (51%)/46 (49%) 21 (41%)/30 (59%) 26 (62%)/16 (34%) 0.047
Postoperative data
Radiation therapy postoperatively 45 (50%) 20 (43%) 25 (58%) 0.211
Chemotherapy postoperatively 20 (23%) 8 (17%) 12 (29%) 0.326
DEX: dexamethasone group.
NON-DEX: non-dexamethasone group.
BMI: Body Mass Index.
ASA: American Society of Anesthesiologists.
CCI: Charlson Comorbidity Index.
Alcohol use was defined as moderate if drinking was weekly or less and major if it occurred daily.
Patients were defined as smokers if they smoked before surgery.
Data given as median and range.
Table 2
Surgical data.
All (n = 93) DEX (n = 51) NON-DEX (n = 42) P
Reconstruction type: Soft tissue/bone 83/10 46/5 37/5 0.745
Primary lesion
Tongue 27 13 14
Floor of mouth 11 8 3
Mandible 26 14 12
Maxilla 15 9 6
Buccal mucosa 9 5 4
Tonsilla 3 1 2
Palate 1 1 0
Larynx - hypofarynx 1 0 1
Flap type 0.360
Forearm flap 51 31 20
ALT 33 15 18
DCIA 4 2 2
Fibula 1 1 0
LD 1 0 1
Scapula + LD 2 0 2
Scapula + parascapula 1 1 0
Neck dissection 0.207
Unilateral 78 45 33
Bilateral 15 6 9
Neck dissection levels 0.201
Sentinel 10 7 3
L1-3 28 18 10
L1-4/5 or radical 55 26 29
Operation time (min) 340 (87–975) 340 (138–975) 359 (208–719) 0.373
DEX: dexamethasone group.
NON-DEX: non-dexamethasone group.
ALT: Anterolateral Thigh Perforator flap.
LD: latissimus dorsi muscle.
DCIA: The deep circumflex iliac artery bone flap.
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tions. Two patients in the DEX group and one patient in the NON-
DEX group had more than one major complication. Minor compli-
cations included those that only required local treatment bed-side
or drug treatment and did not need surgical interventions in the
operation room. Seven recorded minor complications occurred,four in the DEX group (10%) and three in the NON-DEX group
(12%). The difference between the groups was not significant
(Table 4).
Seventeen cases (18%) developed infections within 14 days of
the operation. These were all treated with a change in antibiotics
and then categorized into the infection group. Infections included
Table 3
Primary outcome measures.
All (n = 93) DEX (n = 51) NON-DEX (n = 42) P
Neck swelling (cm) (n = 77)a 5.5 (0–13) 5.0 (0–12.5) 6.0 (1.5–13) 0.196
Length of ICU stay (days) (n = 93) 3 (1–12) 3 (1–12) 3 (1–8) 0.965
Length of hospital stay (days) (n = 91) 13 (5–49) 12 (5–35) 13 (6–49) 0.594
Duration of tracheostomy (days) (n = 46) 8 (2–43) 6 (2–18) 9 (2–42) 0.251
Duration of intubation (days) (n = 47) 1 (0–6) 1 (1–6) 1 (0–5) 0.064
Start of radiation therapy postoperatively (days) (n = 33) 43 (30–99) 47 (34–99) 43 (30–74) 0.110
DEX: dexamethasone group.
NON-DEX: non-dexamethasone group.
Data given as median and range.
a Highest increase (cm) in neck circumference during the seven postoperative days.
Table 4
Complications.
ALL (n = 93) DEX (n = 51) NON-DEX (n = 42) P
Number of major complications (patients) 17/93 (18%) 14/51 (27%) 3/42 (7%) 0.012
Number of major complications 20 16 4
Venous thrombosis 6 (6%) 4 (8%) 2 (5%)
Flap loss 3 (3%) 2 (4%) 1 (2%)
Wound necrosis, fistula, infection 4 (4%) 4 (8%) 0
Postoperative bleeding 1 (1%) 1 (2%) 0
Later tracheostomy 5 (4%) 4 (8%) 1 (2%)
Pneumothorax 1 (1%) 1 (2%) 0
Number of minor complications (patients) 7/93 (11%) 4/51 (10%) 3/42 (12%) 0.899
Fluid collection/seroma 2 (2%) 1 (2%) 1 (2%)
Local wound infection (neck or face) 1 (1%) 1 (2%) 0
Hematoma/bleeding 3 (3%) 1 (2%) 2 (5%)
Fistula 1 (1%) 1 (2%) 0
Infection postoperatively 17/94 (18%) 10/51 (20%) 7/42 (17%) 0.715
DEX: dexamethasone group.
NON-DEX: non-dexamethasone group.
Data given as median and range.
Table 5
TNM classification.
N0 N1 N2A-C TOTAL
DEX NON-DEX DEX NON-DEX DEX NON-DEX
T1 - T2 22 12 2 6 3 6 51
T3 - T4A-B 12 10 2 1 9 6 40
TOTAL 34 22 4 7 12 12 91
% of n 68% 54% 8% 17% 24% 29%
DEX: dexamethasone group.
NON-DEX: non-dexamethasone group.
DEX n = 50.
NON-DEX n = 41.
Data is missing from two patients (1 from DEX group and 1 from NON-DEX group).
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bophlebitis (n = 1), surgical wound infection in the neck not need-
ing surgical operation (n = 4), and infection of unknown origin
(n = 5). There was no significant difference in the infection rate
between the study group and control group (Table 4). Duration
of intravenous antibiotic treatment ranged from three days to
30 days, and the median length was eight days in the DEX group
and seven days in the NON-DEX group. A subgroup analysis was
performed and there were not more minor or major complications
or infections in the diabetic group that got dexamethasone than in
the NON-DEX group.
In multivariate analysis, significant associations with recovery
time were found for alcohol use and each of the major complica-
tions, but the associations were similar for both study groups.
According to multivariate logistic regression, not having a major
complication (OR 16.1, 95% CI 2.5–107.9, p = 0.004) and higher
BMI (OR 1.1, 95% CI 1.0–1.3, p = 0.042) were significantly associ-ated with shorter/better recovery. Those with major use of alcohol
(OR 0.07, 95% CI 0.01–0.5, p = 0.011) had a significantly lower prob-
ability of having a shorter and better recovery than those who did
not use any alcohol; the same was true for those with ASA 3 (OR
0.03, 95% CI 0.001–0.9, p = 0.046) or ASA 4 (OR 0.01, 95% CI
0.001–0.2, p = 0.010) compared with those with ASA 1. No differ-
ence was present between the groups in amount of nausea.
We used a two-sided Fisher’s exact test with a significance level
of 0.05 for retrospective power analysis for a test of the two inde-
pendent proportions, i.e., occurrence of tracheostomy and periop-
erative use of dexamethasone. With the slightly unbalanced
design (n = 21 in the dexamethasone group and n = 26 in the con-
trol group) and the rates observed (41%/62%), we estimated a
power of 0.81, which reaches the commonly used standard
(0.80 6 1  b 6 0.95). Length of tracheostomy was three days
shorter (23%) in the DEX group, but the difference was not signifi-
cant. We used a two-sample Satterthwaite t-test assuming unequal
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power analysis for a test of the two independent means, i.e.,
duration of tracheostomy (days) and perioperative use of
dexamethasone. With the slightly unbalanced design (n = 20 in
the dexamethasone group and n = 24 in the control group) and
the means observed (8.3 with SD 5.0/11.2 with SD 8.7), we
estimated a power of 0.31, which is clearly below the commonly
used standard (0.80 6 1  b 6 0.95).Discussion
We performed a prospective double-blind controlled study in
head and neck cancer patients with microvascular reconstruction
and randomized patients to either receive dexamethasone or not.
To our knowledge, this is the first study focusing on the use of
GCs in major microvascular reconstruction patients. The patients
stayed as long in the intensive care unit and ward, the duration
of intubation was the same, and no difference was present in the
delay to start of adjuvant radiotherapy between patients receiving
dexamethasone and those who did not. There was a trend for a
shorter duration of tracheostomy in the DEX group and a power
analysis confirmed that the study size was sufficient to conclude
that this difference was not statistically significant. We did not find
any benefit in the use of dexamethasone with regard to our pri-
mary outcome measures.
A systematic review of the literature and meta-analysis by Dan
et al. showed that the administration of GCs decreases edema and
pain significantly in oral surgery [11]. Pedersen [27], Skjelbred
[28], and Milles [29] found a significant decrease in edema but
not in pain with low-dose GCs. Neupert et al. reported a significant
decrease in pain, but not in edema [30]. We expected the amount
of postoperative neck edema, which was measured seven days
postoperatively, to be significantly less in the DEX group, but no
difference emerged between the groups. In addition, we observed
no difference in the amount of nausea between those receiving
and not receiving dexamethasone. We therefore conclude that
GCs provided no beneficial effects in our head and neck cancer
patients undergoing microvascular reconstruction.
Major complications occurred more frequently in patients
administered GCs than in the control group. In addition, all infec-
tions that needed surgical interventions occurred in patients
receiving dexamethasone. Dexamethasone is often given to reduce
the risk of postoperative nausea and vomiting, but steroid-induced
immunosuppression can increase infection risk by impairing
innate immune responses and healing. Previous evidence has also
shown contradictory results regarding the influence of periopera-
tive GCs on postoperative complications and infections
[23,31,32]. Percival et al. [22] concluded that intraoperative
administration of dexamethasone for anti-emetic purposes may
confer an increased risk of postoperative infection. The operations
in their analysis included orthopedic, thoracic, neurosurgical, oto-
laryngologic, vascular, plastic, breast, urology, colonic, and gas-
troenterological procedures, but the amounts of dexamethasone
were relatively small. By contrast, the meta-analysis by Dan et al.
[11] showed that giving GCs during oral surgery did not signifi-
cantly increase the risk of infection. In our study, infections treated
with antibiotics were similar between the groups, but surgical
infections needing secondary surgery within three weeks and clas-
sified as major complications occurred more often in the DEX
group; this difference was significant.
The randomization in this study succeeded because there were
only minor differences in the demographic and perioperative data
between the two groups. The only intergroup differences were
more heavy alcohol users in the NON-DEX group and more tra-
cheostomized patients in the DEX group. However, four patientsin the DEX group and one patient in the NON-DEX group needed
to be tracheostomized postoperatively. There was a trend for more
diabetics in the DEX group, however in a subgroup analysis diabet-
ics in the DEX group did not have more complications than the
NON-DEX group. Since the main finding of this study is the higher
number of major complications in the DEX group, we conclude that
these differences in patient groups did not confound the result. The
patient population with head and neck neoplasms is largely an
elderly population, and these patients often have significant histo-
ries of smoking and alcohol consumption. These patients are also
more likely to have comorbidities. Various predictors of complica-
tions have been proposed and investigated widely such as age, his-
tories of smoking and alcohol consumption, comorbidities,
preoperative radiation, and chemoradiotherapy. Le Nobel et al.
[33] retrospectively analyzed perioperative complications follow-
ing 304 free flap reconstructions in the head and neck and investi-
gated potential predictors of these complications. They suggested
that head and neck free flap reconstruction can be done safely
and effectively despite advanced age of the patient and high fre-
quency of comorbid conditions. In our material, multivariate anal-
ysis revealed significant associations with recovery time for
alcohol use and major complications, but the associations were
similar for both study groups. Age and comorbidities did not
increase complication risk for free flap patients.
We conclude that in this prospective randomized double-blind
study of head and neck cancer patients with microvascular recon-
struction the use of dexamethasone did not benefit the patients.
Patients receiving dexamethasone did not have shorter visits in
the intensive care unit or ward, nor did they show decreased tra-
cheostomy or intubation times. There was no difference in the
swelling of the neck between the groups. However, more major
complications, especially infections, occurred in patients receiving
dexamethasone. Our findings thus do not support the use of peri-
and postoperative dexamethasone in head and neck cancer
patients with microvascular reconstruction.
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